Has Mazen Jizzini received payments from drug or device companies?

Yes. Drug and device makers reported $3,962 in general payments to Mazen Jizzini across 94 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mazen Jizzini did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mazen Jizzini come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mazen Jizzini

Hematology & Oncology · Tarzana, CANPI 1346702032

Payments from drug & device makers

$3,962in general payments, 2019–2025

Across 94 payments — averaging $42.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$531
Sanofi$460
Gilead$435
EMD Serono, Inc.$298
Blueprint Medicines Corporation$271
Johnson & Johnson$245
plus $2K from 23 others

What the payments were for

Food & beverage$3,52789%
Education$43511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	17	$531
Sanofi	14	$460
Gilead(2 entities)	6	$435
EMD Serono, Inc.	6	$298
Blueprint Medicines Corporation	3	$271
Johnson & Johnson	5	$245
Aadi Bioscience, Inc.	2	$183
Seagen Inc.	2	$171
Secura Bio, Inc.	1	$135
Karyopharm Therapeutics Inc.	1	$131
AstraZeneca	7	$125
Sobi, Inc	1	$124
Astellas Pharma US Inc	2	$123
Bristol Myers Squibb	4	$95
Genentech USA, Inc.	3	$87
Incyte Corporation	2	$87
Jazz Pharmaceuticals Inc.	3	$81
Takeda Pharmaceuticals U.S.A., Inc.	2	$60
Agios Pharmaceuticals, Inc.	2	$47
Regeneron Healthcare Solutions, Inc.	1	$39
Daiichi Sankyo Inc.	2	$35
Rigel Pharmaceuticals, Inc.	1	$31
Progenics Pharmaceuticals, Inc.	1	$30
Beone Medicines USA, Inc.	1	$28
Amgen	1	$26
Geron Corporation	1	$24
Merck	1	$23
Deciphera Pharmaceuticals Inc.	1	$22
E.r. Squibb & Sons, L.L.C.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,962 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Acyclovir	14	$203

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Tarzana

Alain AlgaziSan Francisco$119.2M
David BerzLos Angeles$43.3M
Jonathan GoldmanSanta Monica$35.7M
Omid HamidSanta Monica$23.7M
Nicholas McAndrewLos Angeles$22.9M
Aditya BardiaSanta Monica$22.1M
Joseph TuscanoSacramento$20.4M
Zev WainbergSanta Monica$19.3M
Caitlin CostelloSan Diego$16.9M
Rana McKaySan Diego$15.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →